Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 4/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | KRAS | P01116 | 2/20 | 0.36 |
| ▸ | RAF1 | P04049 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | LYN | P07948 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18306364 | 0.82 | ABL1 (0.40) | KMT2APOLBABL1KITKDR | |
| SCHEMBL18712024 | 0.78 | RAB9A (0.38) | MEN1KMT2APOLBMAPTABL1 | |
| SCHEMBL18306350 | 0.77 | TGFBR1 (0.39) | ABL1KITNTRK1KDRLCK | |
| SCHEMBL19654959 | 0.77 | TGFBR1 (0.40) | KITKDRROCK2LIMK1LCK | |
| SCHEMBL19661652 | 0.73 | DHODH (0.38) | MAPTKDRRAF1BRAFMAPK1 | |
| SCHEMBL15638949 | 0.70 | GRM2 (0.46) | ABL1KDR | |
| SCHEMBL17177325 | 0.70 | ABL1 (0.36) | ABL1KITNTRK1KDRBRAF | |
| SCHEMBL18306371 | 0.70 | TGFBR1 (0.40) | MEN1KMT2ANTRK1KDRCSF1R | |
| SCHEMBL15637353 | 0.69 | TGFBR1 (0.47) | MEN1KMT2A | |
| SCHEMBL18306360 | 0.68 | IRAK4 (0.35) | NTRK1KDRBRAFCSF1RFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170342048-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | TGFBR1, TGFBR2, ACVR1 | MEN1 1279/4885KMT2A 3459/4885POLB 2333/4885 |
| US-20170342048-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | MEN1 444/4885KMT2A 4190/4885POLB 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.